Ligand Pharmaceuticals Incorporated LGND
298.71 USD +4.90 (+1.67%)
Regular-session close
300.94 +2.23 +0.75%
After hours · Nov 18, 7:45 PM ET
292.94 Day range 301.93
175.89 52-week range 326.63
- YTD
- +57.99%
- 1 year
- +44.27%
News
defenseworld.net 3,096 Ligand Pharmaceuticals Incorporated $LGND Shares Acquired by Bessemer Group Inc. Bessemer Group Inc. increased its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.2% during the undefined quarter, according to the company in its most recent disclosure…
defenseworld.net Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Below 50-Day Moving Average After Insider Selling Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock…benzinga.com Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350 Barclays analyst Glen Santangelo maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $345 to $350.
defenseworld.net Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average…
defenseworld.net Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells $1,566,100.00 in Stock Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - Get Free Report) insider Andrew Reardon sold 5,000 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average…benzinga.com Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402 Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $397 to $402.
seekingalpha.com Ligand Pharmaceuticals: Filspari And XOMA Strengthen The Case For A Buy Ligand Pharmaceuticals earns a BUY rating, driven by robust royalty growth and the accretive XOMA acquisition. Filspari's 85% YoY royalty growth and new FSGS indication position it as LGND's leading…benzinga.com RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357 RBC Capital analyst Douglas Miehm maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $345 to $357.
seekingalpha.com Ligand Pharmaceuticals Incorporated (LGND) Q3 2026 Earnings Call Transcript Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2026 Earnings Call October 29, 2026 8:30 AM EDT Company Participants Melanie Herman - Executive Director of Investor Relations and Financial Planning &…
marketbeat.com What Ligand Pharmaceuticals (LGND) Said on Its Q3 Earnings Call Ligand Pharmaceuticals NASDAQ: LGND reported third-quarter royalty revenue growth of 51% year over year to approximately $70 million, driven by Filspari, Ohtuvayre and commercial assets acquired…
benzinga.com Ligand Pharmaceuticals Q3 2026 Earnings Call Transcript Ligand Pharmaceuticals (NASDAQ:LGND) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M Est Ligand Pharmaceuticals (NASDAQ:LGND) raises FY2026 Adj EPS guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 analyst estimate. Lowers FY2026 sales outlook from $270.000 million-$310.000 million to…
benzinga.com Ligand Pharmaceuticals Q3 Adj. EPS $2.67 Beats $2.38 Estimate, Sales $78.700M Beat $77.232M Estimate Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $2.67 per share which beat the analyst consensus estimate of $2.38 by 12.18 percent. This is a 13.59 percent decrease over earnings…
globenewswire.com Ligand Reports Third Quarter 2026 Financial Results Third-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.50 1 ; Reaffirms Revenue Guidance…
globenewswire.com Ligand to Participate in November Investor Conferences JUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor…
benzinga.com Here's How Much $1000 Invested In Ligand Pharmaceuticals 20 Years Ago Would Be Worth Today Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 20 years by 12.04% on an annualized basis producing an average annual return of 20.96%. Currently, Ligand…
globenewswire.com Ligand to Host Investor Day on December 8, 2026 JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from…
globenewswire.com Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026 JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29,…
globenewswire.com Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a…
businesswire.com Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced…
prnewswire.com Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by…
globenewswire.com Ligand Acquires Royalty and Milestone Interest in Santen's Ryjunea® from Sydnexis for $23 Million Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to…
seekingalpha.com Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech Ligand Pharmaceuticals (LGND) is reassessed after a ~10% loss since its last 'Buy' rating. The article focuses on LGND's future prospects, emphasizing its key royalty producing assets. LGND is…
defenseworld.net Reviewing Omeros (NASDAQ:OMER) & Ligand Pharmaceuticals (NASDAQ:LGND) Omeros (NASDAQ: OMER - Get Free Report) and Ligand Pharmaceuticals (NASDAQ: LGND - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
marketbeat.com Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital Ligand Pharmaceuticals NASDAQ: LGND outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage…
globenewswire.com Ligand to Participate in September Investor Conferences JUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced its senior management team will participate in the following upcoming investor…
defenseworld.net Handelsbanken Fonder AB Raises Stake in Ligand Pharmaceuticals Incorporated $LGND Handelsbanken Fonder AB boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the…
